MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix’s investigational prostate cancer imaging agent, Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the Nordic region.
Under the terms of the agreement, Wiik Pharma, a specialist supplier and distributor of nuclear medicine products and services will be the exclusive commercial distributor of Illuccix in Denmark, Finland, Norway and Sweden for a period of three (3) years from the national approval date in each country.
Yacoub Amin, CEO of Wiik Pharma said, “This commercial partnership with Telix marks a major step towards achieving Wiik Pharma’s vision to improve the diagnosis and treatment management of patients with difficult-to-detect and treatment-requiring diseases. We have high expectations for the collaboration with Telix, not just for Illuccix but also for other upcoming diagnostics and therapeutics in their investigational pipeline.”
Raphaël Ortiz, Telix CEO for the Europe, Middle East and Africa (EMEA) region added, “We are pleased to team up with Wiik Pharma, and look forward to bringing gallium-based PSMA-PET imaging to men in need in the Nordics, an important region for Telix. Telix has established a network of leading distribution partners in Europe with a strong footprint to optimise our service to customer sites and ensure we can bring Illuccix to patients across the region, subject to regulatory approval.”
About Prostate Cancer in the Nordic region
In 2020, prostate cancer was the most commonly diagnosed cancer in the Nordic region, with approximately 27,000 new cases, exhibiting a significantly higher incidence than either lung cancer (16,000 new cases) or bowel cancer (21,500 new cases). Prostate cancer was also a leading cause of cancer death in men, with almost 6,000 men dying from the disease in the Nordic region in 2020. A total of 113,000 men in Denmark, Finland, Iceland, Norway and Sweden were estimated to be living with prostate cancer in 2020.
About Wiik Pharma ApS
Wiik Pharma ApS was established in 2015 and is a Danish pharma company specialising in nuclear medicine based in Hinnerup, Denmark. The company supports nuclear medicine departments and positron emission tomography (PET) centers on their way from ligand to diagnostic and therapeutic agents. The company is an authorized radiopharmaceutical provider whose goal is to promote imaging and radionuclide treatment in all the Nordic countries by finding and offering the best practice, no matter where it may be found. For more information visit: www.wiikpharma.dk
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn.
Telix’s lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. Telix is also progressing Marketing Authorisation Applications for 68Ga-PSMA-11 in the United Kingdom, the European Union and Brazil.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.
©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).
 Imaging of prostate-specific membrane antigen with positron emission tomography.
 Globocan 2020.
 Telix ASX disclosure 20 December 2021.
 Telix ASX disclosure 2 November 2021.
 Telix ASX disclosure 14 October 2022.
 Telix ASX disclosure 3 April 2023.